|
|
[General
information | History | Laboratory/Animal/Preclinical
studies]
[Human/Clinical studies
| Adverse effects | Glossary
| References]
[For more information]
References
- Prudden
JF, Balassa, LL: The biological activity of bovine cartilage preparations.
Seminars in Arthritis and Rheumatism 3(4): 287-321, 1974.
- Prudden
JF: The treatment of human cancer with agents prepared from bovine cartilage.
Journal of Biological Response Modifiers 4: 551-584, 1985.
- Romano
CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid
tumors. Journal of Biological Response Modifiers 4(6): 585-589, 1985.
- Puccio
C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma
with Catrix. Proceedings of the American Society of Clinical Oncology
13: A769, 1994.
-
Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of
a novel shark cartilage extract: Potential role in the treatment of
psoriasis. Journal of Cutaneous Medicine and Surgery 2(3): 146-152,
1998.
-
Rivere M, Latreille J, Falardeau P, et al.: AE-941(Neovastat), an inhibitor
of angiogenesis: Phase I/II lung cancer clinical trial results. Annals
of Oncology 9(suppl. 4):133(A636P), 1998.
-
Evans WK, Latreille J, Batist G, et al.: AE-941, an inhibitor of angiogenesis:
Rationale for a phase III study on AE-941 in combination with induction
chemotherapy/radiotherapy in patients with non small cell lung cancer
(NSCLC). Proceedings of the 1999 AACRNCIEORTC International Conference.
Clinical Cancer Research 5: 3774s(A221), 1999.
- Evans
W, Latreille J, Batist G, et al.: AE-941, an inhibitor of angiogenesis:
Rationale for development in combination with induction chemotherapy/radiotherapy
in patients with non small cell lung cancer (NSCLC). Proceedings of
the American Society of Clinical Oncology 18: A1938, 1999.
-
Evans WK, Latreille J, Barist G, et al.: AE-941, an inhibitor of angiogenesis:
Rationale for development in combination with induction chemotherapy/radiotherapy
in patients with non-small-cell lung cancer (nsclc). European Journal
of Cancer 35(suppl. 4): S250(A992), 1999.
-
Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety
and efficacy of shark cartilage in the treatment of advanced cancer.
Journal of Clinical Oncology 16(11): 3649-3655, 1998.
-
Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies
of oral dry shark cartilage powder (SCP) with either metastatic breast
or prostate cancer refractory to standard treatment. Proceedings of
the American Society of Clinical Oncology 17: A240, 1998.
-
Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in
the treatment of patients with advanced primary brain tumors. A phase
II pilot study. Proceedings of the American Society of Clinical Oncology
18: A554, 1999.
-
PDQ Clinical Trials Database (URL: http://cancernet.nci.nih.gov): Phase
II study of the safety and efficacy of bovine tracheal cartilage in
the treatment of advanced or metastatic cancer. Protocol IDs: MRMC-CTCA-9506,
NCI-V96-1027. Status: Closed. Database accessed: July 10, 2000.
- Prudden
JF, Migel P, Hanson P, et al.: The discovery of a potent pure chemical
wound-healing accelerator. The American Journal of Surgery 119(5): 560-564,
1970.
- Anonymous:
Aetema: Clinical results from phase I of the prostate and lung cancer
study confirm the safety of AE-941/Neovastat (press release). European
Journal of Cancer Care 8: 7, 1999.
-
Anonymous: AE 941-Neovastat : Adis comments. Drugs R&D 1(2):135-136,
1999.
-
Cassileth BR: Shark and bovine cartilage therapies. In: The Alternative
Medicine Handbook (WW Norton & Company, New York, NY), pp. 197- 200,
1998.
- The
Center for Alternative Medicine Research in Cancer at the University
of Texas-Houston Health Science Center: Cartilage summary. URL: http://www.sph.uth.tmc.edu:8052/utcam/agents/crtlg.htm.
Date accessed: August 18, 2000.
- Holt
S: Shark cartilage and nutriceutical update. Alternative & Complementary
Therapies 1: 414-416, 1995.
- Anonymous:
Therapy consultation: Shark cartilage for cancer treatment. American
Journal of Health-System Pharmacy 52: 1756/1760, 1995.
- Fontenele
JB, Araujo GB, de Alencar JW, et al.: The analgesic and anti-inflammatory
effects of shark cartilage are due to a peptide molecule and are nitric
oxide (NO) system dependent. Biological and Pharmaceutical Bulletin
20(11): 1151-1154, 1997.
-
Harshbarger JC, Ostrander GK.: Cancer in sharks, skates, rays, and other
lower fishes. Proceedings of the American Association for Cancer Research
41: A4848, 2000.
-
Schlumberger HG, Lucke B: Tumors of fishes, amphibians, and reptiles.
Cancer Research 8: 657-754, 1948.
-
Wellings SR: Neoplasia and primitive vertebrate phylogeny: echinoderms,
prevertebrates, and fishes--a review. National Cancer Institute Monograph
31: 59-128, 1969.
- Durie
BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract
(Catrix-S) in the human tumor stem cell assay. Journal of Biological
Response Modifiers 4(6): 590-595, 1985.
-
Murray JB, Allison K, Sudhalter J, et al.: Purification and partial
amino acid sequence of a bovine cartilage-derived collagenase inhibitor.
Journal of Biological Chemistry 261(9): 4154-4159, 1986.
- Moses
MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization
from cartilage. Science 248: 1408-1410, 1990.
- Moses
MA, Sudhalter J, Langer R: Isolation and characterization of an inhibitor
of neovascularization from scapular chondrocytes. Journal of Cell Biology
119(2): 475-482, 1992.
- Moses
MA: A cartilage-derived inhibitor of neovascularization and metalloproteinases.
Clinical and Experimental Rheumatology 11(suppl. 8): S67- S69, 1993.
-
Takigawa M, Pan H-O, Enomoto, et al.: A clonal human chondrosarcoma
cell line produces an anti-angiogenic antitumor factor. Anticancer Research
10: 311-316, 1990.
-
Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor
from culture medium conditioned by a human chondrosarcoma-derived chondrocytic
cell line, HCS-2/8. Biochimica et Biophysica Acta 1245: 1-8, 1995.
- Sadove
AM, Kuettner KE: Inhibition of mammary carcinoma invasiveness with cartilage-derived
inhibitor. Surgical Forum 28: 499-501, 1977.
- Langer
R, Brem H, Falterman K, et al.: Isolation of a cartilage factor that
inhibits tumor neovascularization. Science 193: 70-71, 1976.
- Langer
R, Conn H, Vacanti J, et al.: Control of tumor growth in animals by
infusion of an angiogenesis inhibitor. Proceedings of the National Academy
of Sciences USA 77(7): 4331-4335, 1980.
-
Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor
factor (CATF) inhibits the proliferation of endothelial cells in culture.
Cell Biology International Reports 9(7): 619-625, 1985.
-
Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium
of rabbit costal chondrocytes inhibits the proliferation of cultured
endothelial cells and angiogenesis induced by B16 melanoma: its relation
with cartilage-derived anti-tumor factor (CATF). Biochemistry International
14(2): 357-363, 1987.
- Hiraki
Y, Inoue H, Iyama K-I, et al.: Identification of chondromodulin I as
a novel endothelial cell growth inhibitor. Journal of Biological Chemistry
272(51): 32419-32426, 1997.
- Pauli
BU, Memoli VA, Kuettner KE: Regulation of tumor invasion by cartilage-derived
anti-invasion factor in vitro. Journal of the National Cancer Institute
67(1): 65-70, 1981.
-
Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis.
Science 221(4616): 1185-1187, 1983.
-
Davis PF, He Y, Furneaux RH, et al.: Inhibition of angiogenesis by oral
ingestion of powdered shark cartilage in a rat model. Microvascular
Research 54(2): 178-182, 1997.
-
Sheu JR, Fu CC, Tsai ML, et al.: Effect of U-995, a potent shark cartilage-derived
angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
Anticancer Research 18: 4435-4442, 1998.
- McGuire
TR, Kazakoff PW, Hoie EB, et al.: Antiproliferative activity of shark
cartilage with and without tumor necrosis factor-a in human umbilical
vein endothelium. Pharmacotherapy 16(2): 237-244, 1996.
- Oikawa T, Ashino-Fuse
H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese
shark cartilage (I): extraction and estimation of inhibitory activities
toward tumor and embryonic angiogenesis. Cancer Letters 51(3): 181-186,
1990.
- Morris GM, Coderre
JA, Micca PL, et al.: Boron neutron capture therapy of the rat 9L gliosarcoma:
Evaluation of the effects of shark cartilage. British Journal of Radiology
73: 429-434, 2000.
- Dupont E, Alaoui-Jamali
M, Wang T, et al.: Angiostatic and antitumoral activity of AE-941 (Neovastat-R),
a molecular fraction derived from shark cartilage. Proceedings of the
American Association for Cancer Research 38: A1530, 1997.
- Riviere M, Alaoui-Jamali
M, Falardeau P, et al.: Neovastat: an inhibitor of angiogenesis with
anti-cancer activity. Proceedings of the American Association for Cancer
Research 39: A317, 1998.
- Sirois MG: AE-941,
a new and specific VEGF antagonist? Proceedings of the American Association
for Cancer Research 40: A1517, 1999.
- Liang JH, Wong
KP: The characterization of angiogenesis inhibitor from shark cartilage.
Advances in Experimental Medicine and Biology 476: 209-223, 2000.
- Wojtowicz-Praga
S: Clinical potential of matrix metalloproteinase inhibitors. Drugs
R&D 1(2): 117-129, 1999.
- Suzuki F: Cartilage-derived
growth factor and antitumor factor: Past, present, and future studies.
Biochemical and Biophysical Research Communications 259: 1-7, 1999.
- PDQ Clinical Trials
Database (URL: http://cancernet.nci.nih.gov): Phase III randomized study
of induction chemotherapy and radiotherapy with or without AE-941, a
shark cartilage extract, in patients with stage IIIA or IIIB unresectable
non-small cell lung cancer. Protocol IDs: MDA-ID-99303, NCI-T99- 0046.
Status: Active. Database accessed: July 10, 2000.
- PDQ Clinical Trials
Database (URL: http://cancernet.nci.nih.gov): Phase III randomized study
of AE-941 (shark cartilage extract) in patients with metastatic renal
cell carcinoma refractory to immunotherapy. Protocol IDs: AETERNA-AE-RC-99-02,
CAN-CCI-ETH-00-32-17, CCF-IRB-3664, JGH-00023, UPCC- 2800. Status: Active.
Database accessed: October 13, 2000.
- Folkman J: The
role of angiogenesis in tumor growth. Seminars in Cancer Biology 3:
65-71, 1992.
- Sipos EP, Tamargo
RJ, Weingart JD, et al.: Inhibition of tumor angiogenesis. Annals of
the New York Academy of Sciences 732: 263-272, 1994.
- Li C-Y, Shan S,
Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis:
Evaluation via skin window chambers in rodent models. Journal of the
National Cancer Institute 92(2): 143-147, 2000.
- Alberts B, Bray
D, Lewis J, et al.: The Molecular Biology of the Cell, Third Edition
(Garland Publishing, New York, NY), 1294 pages, 1994.
- Cremer MA, Rosloniec
EF, Kang AH: The cartilage collagens: A review of their structure, organization,
and role in the pathogenesis of experimental arthritis in animals and
in human rheumatic disease. Journal of Molecular Medicine 76: 275-288,
1998.
- Rosen J, Sherman
WT, Prudden JF, et al.: Immunoregulatory effects of Catrix. Journal
of Biological Response Modifiers 7(5): 498-512, 1988.
- Houck JC, Jacob
RA, DeAngelo L, et al.: The inhibition of inflammation and the acceleration
of tissue repair by cartilage powder. Surgery 51: 632- 638, 1962.
- Simone CB, Simone
NL, Simone CB: Shark cartilage for cancer. Lancet 351: 9113, 1998.
- Horsman MR, Alsner
J, Overgaard J: The effect of shark cartilage extracts on the growth
and metastatic spread of the SCVII carcinoma. Acta Oncologica 37: 441-445,
1998.
- Moses MA: The
regulation of neovascularization by matrix metalloproteinases and their
inhibitors. Stem Cells 15: 180-189, 1997.
- Stetler-Stevenson
WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. Journal of Clinical Investigation 103(9): 1237-1241, 1999.
- Haas TL, Madri
JA: Extracellular matrix-driven metalloproteinase production in endothelial
cells: Implications for angiogenesis. Trends in Cardiovascular Medicine
9(3/4): 70-77, 1999.
- McCawley LJ, Matrisian
LM: Matrix metalloproteinases: Multifunctional contributors to tumor
progression. Molecular Medicine Today 6: 149-156, 2000.
- Pettit GR, Ode
RH: Antineoplastic agents L: isolation and characterization of sphyrnastatins
1 and 2 from the hammerhead shark Sphyrna lewini. Journal of Pharmaceutical
Sciences 66(5): 757-758, 1977.
- Sigel MM, Fugman
RA: Studies on immunoglobulins reactive with tumor cells and antigens.
Cancer Research 28: 1457-1459, 1968.
- Snodgrass MJ,
Burke JD, Meetz, GD: Inhibitory effect of shark serum on the Lewis lung
carcinoma. Journal of the National Cancer Institute 56(5): 981-983,
1976.
- Pugliese PT, Heinerman
J: Devour Disease with Shark Liver Oil (Impakt Communications, Green
Bay, WI), 63 pages, 1999.
- Berberi P, Thibodeau
A, Germain L, et al.: Antiangiogenic effects of the oral administration
of liquid cartilage extract in humans. Journal of Surgical Research
87: 108-113, 1999.
- Ashar B, Vargo
E: Shark cartilage-induced hepatitis. Annals of Internal Medicine 125(9):
780-781, 1996.
back
to top
For
More Information
For more
information on complementary and alternative therapies, contact the National
Institutes of Health (NIH) National Center for Complementary and Alternative
Medicine (NCCAM):
NCCAM Clearinghouse
Post Office Box 8218
Silver Spring, MD 20907-8218
TTY/TDY: 1-888-644-6226 (toll free)
Additional information
is available in the NCI Cancer Facts sheet Questions and Answers About
Complementary and Alternative Medicine in Cancer Treatment.
Important: This information
is intended mainly for use by doctors and other health care professionals.
If you have questions about this topic, you can ask your doctor, or call
the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
This publication is not copyrighted and is in the public domain. Duplication is encouraged.
National Institutes of Health
National Center for Complementary and Alternative Medicine (NCCAM)
NCCAM Clearinghouse.
back
to top
3 of 3
: <<back
|
|
